WO2011014883A3 - Skin rejuvenation and wrinkle treatment by gingival fibroblast and its growth factor: activation of effect by hyluronic acid - Google Patents

Skin rejuvenation and wrinkle treatment by gingival fibroblast and its growth factor: activation of effect by hyluronic acid Download PDF

Info

Publication number
WO2011014883A3
WO2011014883A3 PCT/US2010/044147 US2010044147W WO2011014883A3 WO 2011014883 A3 WO2011014883 A3 WO 2011014883A3 US 2010044147 W US2010044147 W US 2010044147W WO 2011014883 A3 WO2011014883 A3 WO 2011014883A3
Authority
WO
WIPO (PCT)
Prior art keywords
activation
effect
growth factor
skin rejuvenation
wrinkle treatment
Prior art date
Application number
PCT/US2010/044147
Other languages
French (fr)
Other versions
WO2011014883A2 (en
Inventor
Ueda Minoru
Amit Patel
Satoshi Gojo
Original Assignee
Chironcell Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chironcell Inc. filed Critical Chironcell Inc.
Publication of WO2011014883A2 publication Critical patent/WO2011014883A2/en
Publication of WO2011014883A3 publication Critical patent/WO2011014883A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/985—Skin or skin outgrowth, e.g. hair, nails
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein is method a treating UVB-induced wrinkle or photo damaged skin by administering therapeutically effective amount of cultured GF-CM alone or in combination with Hyaluronic Acid subcutaneously via injection.
PCT/US2010/044147 2009-07-31 2010-08-02 Skin rejuvenation and wrinkle treatment by gingival fibroblast and its growth factor: activation of effect by hyluronic acid WO2011014883A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23051109P 2009-07-31 2009-07-31
US61/230,511 2009-07-31
US23070909P 2009-08-01 2009-08-01
US61/230,709 2009-08-01

Publications (2)

Publication Number Publication Date
WO2011014883A2 WO2011014883A2 (en) 2011-02-03
WO2011014883A3 true WO2011014883A3 (en) 2011-07-14

Family

ID=43529980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/044147 WO2011014883A2 (en) 2009-07-31 2010-08-02 Skin rejuvenation and wrinkle treatment by gingival fibroblast and its growth factor: activation of effect by hyluronic acid

Country Status (1)

Country Link
WO (1) WO2011014883A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL237872B1 (en) * 2016-08-01 2021-06-14 Adamed Consumer Healthcare Spolka Akcyjna Composition to be used on skin
WO2018091698A1 (en) * 2016-11-18 2018-05-24 Scarcell Therapeutics Compositions useful for the treatment of immune-related diseases
WO2018190070A1 (en) 2017-04-12 2018-10-18 日本電気株式会社 First base station, second base station, terminal device, method, program, and recording medium

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068297A1 (en) * 2001-08-18 2003-04-10 Deepak Jain Composition and methods for skin rejuvenation and repair
WO2007001016A1 (en) * 2005-06-29 2007-01-04 National University Corporation Nagoya University Dermal tissue improving material and use thereof
WO2008081818A1 (en) * 2006-12-28 2008-07-10 National University Corporation Nagoya University Material for ameliorating skin tissue and method for producing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068297A1 (en) * 2001-08-18 2003-04-10 Deepak Jain Composition and methods for skin rejuvenation and repair
WO2007001016A1 (en) * 2005-06-29 2007-01-04 National University Corporation Nagoya University Dermal tissue improving material and use thereof
WO2008081818A1 (en) * 2006-12-28 2008-07-10 National University Corporation Nagoya University Material for ameliorating skin tissue and method for producing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OHSHIMA, M. ET AL.: "Hepatocyte growth factor secreted by periodontal ligament and gingival fibroblasts is a major chemoattractant for gingival epithelial cells", JOURNAL OF PERIODONTAL RESEARCH, vol. 36, 2001, pages 377 - 383 *
YOSHINO, H. ET AL.: "Mechanical stress induces production of angiogenic regulators in cultured human gingival and periodontal ligament fibroblasts", JOURNAL OF PERIODONTAL RESEARCH, vol. 38, 2003, pages 405 - 410 *

Also Published As

Publication number Publication date
WO2011014883A2 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
NZ710157A (en) Use of guanethidine for treating hypertension by local vascular delivery
WO2012174464A3 (en) Needle for delivery of dermal filler threads
CA3010395A1 (en) Method of treating skin with microrna modulators
WO2010065671A3 (en) Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
RU2014114649A (en) SYNTHESIS OF ELASTIC FIBER IN VIVO
WO2011069141A3 (en) Interferon therapies in combination with blockade of stat3 activation
MX2014004458A (en) Threads of cross-linked hyaluronic acid and methods of use thereof.
WO2010048087A3 (en) Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
NZ591037A (en) Wound healing using choroid plexus secreted proteins
WO2011146926A3 (en) Systems and methods for treatment of sleep apnea
WO2011014883A3 (en) Skin rejuvenation and wrinkle treatment by gingival fibroblast and its growth factor: activation of effect by hyluronic acid
MX2009007247A (en) Method for the treatment of conditions associated with increased 5-lipoxygenase and/or leukotriene activity.
WO2014036556A3 (en) Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
WO2013190567A3 (en) Composition and method for an intradermal hair growth solution
WO2012174224A3 (en) Methods for administering nucleic acid-based therapeutics
EP2381956A4 (en) Treatment of soft tissue injury using hyaluronic acid and botulinum toxin
AU2011274224A8 (en) Keloid treatment
WO2008097535A3 (en) Method of treating atherosclerosis, dyslipidemias and related conditions
WO2010132690A3 (en) Compositions and methods for promoting tissue repair and wound healing
MX2010012454A (en) Method of promoting wound healing.
WO2012016229A3 (en) Oxytocin treatment to improve memory and modify blood glucose
MX2012007234A (en) Calcipotriol monohydrate nanocrystals.
MX2011009212A (en) Medicinal cosmetic lipoatrophy.
WO2008106177A3 (en) Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy
WO2010117992A3 (en) Coupled identification and treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10805179

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10805179

Country of ref document: EP

Kind code of ref document: A2